Durvalumab with platinum-based chemotherapy, then with or without olaparib, for treating newly diagnosed advanced or recurrent endometrial cancer ID6317

  • In development
  • GID-TA11340
  • Expected publication date: TBC

 

Notice of Appeal


Durvalumab with platinum-based chemotherapy, then with or without olaparib, for treating newly diagnosed advanced or recurrent endometrial cancer ID6317

NICE has received 1 appeal, that fall within one or more of the two strictly limited grounds for appeal, against the Final Draft Guidance on the above technology from the following organisation:

  •  AstraZeneca

 The appeal panel will convene on Thursday 2 October at 10:00am via Zoom to hear oral representations from the appellant.

 Members of the public, including consultees and commentators for this appraisal, and the press, may request to attend the hearing.

 Where possible, requests to attend should be made using the registration link that will be available on our website from Friday 25 July 2025. The registration period for this appeal will end at 4:00pm on Thursday 25 September 2025.

 Further details relating to public attendance at this appeal are available on the same webpage as above.